CMC Biologics

www.cmcbio.com

CMC Biologics also offers non-exclusive license to CHEF1™, a proprietary CHO cell line development platform. CHEF1 delivers stable, high-titer, production-quality cell lines in optimized time frames. It is the foundation of CMC Biologics’ innovative approach to cell line and process development.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

HESKA TO ACQUIRE LIGHTDECK DIAGNOSTICS TO INVEST IN MANUFACTURING CAPABILITIES AND ACCELERATE RESEARCH AND DEVELOPMENT EFFORTS

LightDeck Diagnostics and Heska | September 13, 2022

news image

Heska Corporation a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities. Founded in 2009 and headquartered in Boulder, Colorado, LightDeck has develope...

Read More

Industrial Impact

PRECIGEN ENTERS INTO AGREEMENT TO DIVEST NON-HEALTHCARE SUBSIDIARY TRANS OVA GENETICS

Precigen, Inc. | July 06, 2022

news image

Precigen, Inc. a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. an industry-leading animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership, for $170 million in upfront cash and up to $10 million earn-out ba...

Read More

Industrial Impact

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

news image

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More

AI

DEARGEN ANNOUNCES NEW MODEL FOR OPTIMIZING DRUG CANDIDATE MOLECULES WITH NEARLY DOUBLED PERFORMANCE COMPARED TO EXISTING MODELS

Deargen | April 12, 2021

news image

Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time. The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM ...

Read More
news image

Industrial Impact

HESKA TO ACQUIRE LIGHTDECK DIAGNOSTICS TO INVEST IN MANUFACTURING CAPABILITIES AND ACCELERATE RESEARCH AND DEVELOPMENT EFFORTS

LightDeck Diagnostics and Heska | September 13, 2022

Heska Corporation a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities. Founded in 2009 and headquartered in Boulder, Colorado, LightDeck has develope...

Read More
news image

Industrial Impact

PRECIGEN ENTERS INTO AGREEMENT TO DIVEST NON-HEALTHCARE SUBSIDIARY TRANS OVA GENETICS

Precigen, Inc. | July 06, 2022

Precigen, Inc. a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. an industry-leading animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership, for $170 million in upfront cash and up to $10 million earn-out ba...

Read More
news image

Industrial Impact

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More
news image

AI

DEARGEN ANNOUNCES NEW MODEL FOR OPTIMIZING DRUG CANDIDATE MOLECULES WITH NEARLY DOUBLED PERFORMANCE COMPARED TO EXISTING MODELS

Deargen | April 12, 2021

Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time. The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us